Serina Therapeutics (FRA:2BO) Current Accrued Expense: €0.70 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2BO Serina Therapeutics Inc FRA:2BO
20 GF Score
Price €2.04
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Current Accrued Expense?

Serina Therapeutics FRA:2BO -3.77% 20 Current Accrued Expense is €0.70 Mil as of Jun. 2026. GuruFocus rates FRA:2BO with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Serina Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0.70 Mil.

Serina Therapeutics's quarterly Current Accrued Expense increased from Dec. 2025 (€0.34 Mil) to Mar. 2026 (€0.55 Mil) and increased from Mar. 2026 (€0.55 Mil) to Jun. 2026 (€0.70 Mil).

Serina Therapeutics's annual Current Accrued Expense increased from Dec. 2023 (€0.53 Mil) to Dec. 2024 (€0.54 Mil) but then declined from Dec. 2024 (€0.54 Mil) to Dec. 2025 (€0.34 Mil).

Serina Therapeutics Current Accrued Expense Related Terms

Serina Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Current Accrued Expense Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.01 0.01 0.53 0.54 0.34

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.45 0.34 0.55 0.70
FRA:2BO
20GF Score
Serina Therapeutics Inc FRA:2BO
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.70 Mil mean?
Serina Therapeutics (FRA:2BO) has a Current Accrued Expense of €0.70 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Serina Therapeutics and its competitors.
Is Serina Therapeutics' Current Accrued Expense too high?
Serina Therapeutics' current Current Accrued Expense is €0.70 Mil. Overall, Serina Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Current Accrued Expense compare to HRTX and IMA?
Serina Therapeutics' Current Accrued Expense of €0.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Current Accrued Expense is €0.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current Current Accrued Expense of €0.70 Mil. The current Current Accrued Expense is €0.70 Mil. Serina Therapeutics' overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current Current Accrued Expense is €0.70 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
20GF Score

Get the complete analysis for FRA:2BO

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.04
Price